The company’s revenue from operations has been registered at Rs 1726 million
Sanofi Consumer Healthcare India announced the Q1 results with PAT at Rs 500 million, which stands 12.9 per cent above the last quarter of Q4 2024. With an increase of Rs 2.4 per share, landing the EPS at Rs 21.7. The company reported revenue from operations of Rs 1726 million.
Himanshu Bakshi, MD, Sanofi Consumer Healthcare India, “We continue to focus on strengthening our operations and continue to bring superior, simple and accessible products that enable consumers to control their health. Our commitment to delivering high-quality, science-backed products remains at the core of our integrated growth strategy.”
The Q1 2025 also witnessed a successful launch of Allegra D, an addition to the existing portfolio of Allegra variants in India; a brand with over 25 years legacy in India. Q1 2025 and Q1 2024 are not directly comparable, due to demerger and voluntary product recall of certain variants of key brands.
